Navigation Links
New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
Date:12/6/2010

SEATTLE, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("the Company") (Nasdaq and MTA: CTIC) today announced new pixantrone end of study ("EOS") follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application (the "MAA") currently under review by the European Medicines Agency ("EMA").

The end-of-study results showed continued improvement in the trial's primary and secondary endpoints with increased statistical confidence around the endpoint results. At EOS, CR/CRu (Complete Response ("CR")/Complete Response unconfirmed) rate increased to 24% in the pixantrone arm compared to 7% among comparator recipients (p=0.009) while ORR (Overall Response Rate) increased to 40% versus 14% for comparator recipients (p=0.001). The median duration of CR/CRu was 9.6 months for the pixantrone group compared to 4.0 months for the comparator group. Pixantrone patients experienced a 40% reduction in the risk of death or progression over the two year study observation and follow up period compared to standard chemotherapy (p=0.005, HR=0.60) and a 21% reduction in the overall risk for dying (p= 0.25, HR =0.79).  The most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of serious infections was comparable between arms. Deaths due to an adverse event were identical between both arms; there were more LVEF reductions in pixantrone arm, however only two were grade 3 and all were asymptomatic. The results were presented by Principal Investigator, Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the phase III PIX301 EXTEND trial. "The end of study results strengthen the confidence and stability across the primary and secondary measures of efficacy," noted Dr. Pettengell.  "The magnitude of complete and durable
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
6. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
7. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
8. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
9. Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ Virtual ... 2014, from 12:00 to 1:00 p.m. EDT. The session ... and practice-oriented instruction, designed for working professionals. Participants will ... their career in the biotechnology industry. , If interested ... About UMBC’s Biotechnology Graduate Programs, UMBC offers a variety ...
(Date:9/13/2014)... Boehringer Laboratories Inc., with a forty year history ... successful broadcast of a live surgery by St. Luke’s ... FAMBS, and Maher El Chaar, MD, FACS, FAMBS, using ... This sleeve gastrectomy surgery was performed and broadcast live ... surgeons from around the world during the 5th International ...
(Date:9/12/2014)... Advancing the front lines of ... and biological threats is the mission of an ... (WPI) and the Georgian National Academy of Sciences, ... and Security Programme of the North Atlantic Treaty ... Workshop series, the event is titled “Nanotechnology to ...
(Date:9/12/2014)... On Thursday, September 11, 2014, the ... Industrial Average finished the day 0.12% lower at 17,049.00, and ... were broad based as seven out of ten sectors ended ... Index ended the day at 741.83, down 0.33%, while the ... has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... word of the day last Thursday at the ... representatives from across Wisconsin told the tales of their ... broad spectrum of industries represented, ranging from prescription drugs ... radio frequency identification technology could be tailored to fit ...
... the economic downturn in Wisconsin to be over. , ,You dont ... allow me to sing a chorus of Happy Days Are Here ... , ,A pile of available evidence proclaims that Wisconsins economy is ... to 4.8 percent in May, down from 5.1 percent in April. ...
... a national priority , ,MADISON - Kathleen Heuer, ... the U.S. Department of Health and Human Services, and ... of the National Health Information Infrastructure at HHS, will ... being held June 22-23, at the Fluno Center in ...
Cached Biology Technology:Upgrading your business with RFID 2Upgrading your business with RFID 3The economy has come roaring back or is that roar just a purr? 2The economy has come roaring back or is that roar just a purr? 3U.S. Health and Human Services officials to speak at the Digital Healthcare Conference 2
(Date:9/15/2014)... to a morphine regimen can result in better pain ... reduce the dosage of the opioid needed to be ... Indiana University. , The result could bring significant relief ... often felt in the arms and legs and associated ... unmet need for better treatments for neuropathic pain," said ...
(Date:9/15/2014)... all kingdoms of life and constitute a large family ... activities. The presence of halogen substituents in many bioactive ... , One of the Holy Grails in ... incorporation of a halogen atom into a complex natural ... the most inert chemical bonds known in an organic ...
(Date:9/15/2014)... Australia,s leading coral reef ecologists fears that reef biodiversity ... survival that we once thought. , In an international ... Centre of Excellence for Coral Reef Studies (Coral CoE) ... important species within reef ecosystems. , In coral reefs, ... jobs that keep the ecosystem safe and functioning. ...
Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2Pitt chemical biologist finds new halogenation enzyme 2Specialized species critical for reefs 2
... Top 100 Internet Retailers, BOISE, Idaho, Oct. ... provider of fraud control for ecommerce merchants, has ... National Account Sales,directors. Together, they bring Kount customers ... ecommerce fraud control and online,payments., Scott Lewer ...
... pine beetle moves through the forest boring tunnels inside the bark ... competitor. The helper is a fungus that the insect plants inside ... is a tiny, hitchhiking mite, which likewise carries a fungus for ... millennia-old arrangement has grown even more curious. Writing in the Oct. ...
... experiments, biomedical engineers at the Johns Hopkins University School of ... can slow or stop the growth of cells that make ... in the Proceedings of the National Academy of Sciences, ... treatments to fight diseases that depend on the growth of ...
Cached Biology News:Kount Lands Veteran Fraud Experts From Retail Decisions and iovation 2Wielding microbe against microbe, beetle defends its food source 2Wielding microbe against microbe, beetle defends its food source 3Discovery of natural compounds that could slow blood vessel growth 2
... Luminometer has been designed,for the detection ... measurements of glow and flash luminescence ... light remain nearly constant,over a longer ... for very fast reactions,requiring at least ...
... SpliceArray is a new generation of microarrays ... Service enables you to rapidly elucidate alternatively ... be relevant for drug discovery. The service ... probe design and customized analysis with Agilents ...
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
... Immuno-Blot PVDF membrane and filter paper sandwiches ... membrane and two sheets of thick filter ... membrane and filter paper sandwich. These 7 ... binding capacity immunoblotting fit Ready Gel-sized gels ...
Biology Products: